KERYX BIOPHARMACEUTICALS Aktie

1,37 EUR -0,5084%

Zu Ihrem Onlinebroker

kaufen verkaufen

KERYX BIOPHARMACEUTICALS Aktienkurs : 25.05. ( 15 Min. verzögert)
1,37 € Letzter Kurs	-0,51% Veränderung	1,38 € Vortag	1,38 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
1,38 - 1,37 Tag	3,82 - 0,994 52 Wochen	0 Tag	141 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

KERYX BIOPHARMACEUTICALS Akti…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

21.05.

Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex(TM ...

NEW YORK, May 21, 2012 /PRNewswire via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior...
21.05.

M&A Activity and Growing Rate of FDA Approvals Contributing Factors to Biotech ...

The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Keryx Biopharmaceuticals (NASDAQ:KERX) and CytRx Corporation (NASDAQ:CYTR) . "In 2011, the US FDA approved 30 new drugs, compared to 21 in 2010.

16.05.

The Case for Keryx Biopharmaceuticals (NASDAQ:KERX): Analyst Upgrade May Be ...

By VFC's Stock House An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals (NASDAQ:KERX) had shares heavily on the move over the past week, a move initially sparked, in part, by positive Phase...
16.05.

The Case For Keryx Biopharmaceuticals' Analyst Upgrade May Be Justified

An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals (KERX) had shares heavily on the move over the past week, a move initially sparked, in part, by positive Phase...
11.05.

Keryx Biopharmaceuticals Rating Increased to Buy at Ladenburg Thalmann (KERX)

Keryx Biopharmaceuticals (NASDAQ: KERX) was upgraded by equities research analysts at Ladenburg Thalmann from a “neutral” rating to a “buy” rating in a research note issued to investors on Thursday. …